Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment.

Gut - 1 Jul 2022

Wang Feng, Huang You-Sheng, Wu Hao-Xiang, Wang Zi-Xian, Jin Ying, Yao Yi-Chen, Chen Yan-Xing, Zhao Qi, Chen Shifu, He Ming-Ming, Luo Hui-Yan, Qiu Miao-Zhen, Wang De-Shen, Wang Feng-Hua, Xu Mingyan, Li Yu-Hong, Xu Rui-Hua

Abstract excerpt

OBJECTIVE: Circulating tumour DNA (ctDNA) sequencing is increasingly used in the clinical management of patients with colorectal cancer. However, the genomic heterogeneity in ctDNA during treatments and its impact on clinical outcomes remain largely unknown. DESIGN: We conducted a prospective cohort study (NCT04228614) of 171 patients with unresectable metastatic colorectal cancer (mCRC) who underwent first-line...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Colonic Neoplasms

Share to Colorectal Neoplasms

Share to Genomics

Share to Proto-Oncogene Proteins B-raf

Share to Rectal Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 34489309
DOI: 10.1136/gutjnl-2021-324852
PMCID: PMC9185813

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment.PMID 34489309Read ↗

RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.Semantic proximity Read ↗

Temporal dynamics of RAS mutations in circulating tumor DNA in metastatic colorectal cancer: clinical significance of mutation loss during treatment.Semantic proximity Read ↗

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancerSemantic proximity Read ↗

Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis.Semantic proximity Read ↗

Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment.Semantic proximity Read ↗

Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal CancerSemantic proximity Read ↗

Clinical utility of longitudinal circulating tumor DNA analysis in metastatic colorectal cancer patients receiving palliative chemotherapy.Semantic proximity Read ↗

Prognostic Relevance of ctDNA RAS Mutation in Patients With Metastatic Colorectal Cancer Treated With Cetuximab.Semantic proximity Read ↗

Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS MutationSemantic proximity Read ↗

Analysis of Circulating Tumor DNA in Synchronous Metastatic Colorectal Cancer at Diagnosis Predicts Overall Patient Survival.Semantic proximity Read ↗

Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy: Time to Rethink Our Approach.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.